PTC Therapeutics, Inc. (PTCT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 771.07M USD | Liabilities, Current |
| Cash and equivalents | 1.05B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 1.18B USD | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 91.35M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $771.07M | $1.05B | $1.18B | (m) | $91.35M | (m) |
| 2026-03-31 | (m) | $923.60M | $833.99M | $1.06B | (m) | $75.57M | (m) |
| 2025-12-31 | (m) | $968.43M | $984.65M | $960.72M | (m) | $79.65M | (m) |
| 2025-09-30 | (m) | $866.25M | $672.62M | $1.02B | (m) | $52.69M | (m) |
| 2025-06-30 | (m) | $627.81M | $1.02B | $971.76M | (m) | $34.06M | (m) |
| 2025-03-31 | (m) | $595.39M | $1.48B | $546.95M | (m) | $21.68M | (m) |
| 2024-12-31 | (m) | $580.98M | $779.71M | $359.99M | (m) | $23.19M | (m) |
| 2024-09-30 | (m) | $610.71M | $526.00M | $487.36M | (m) | $35.67M | (m) |
| 2024-06-30 | (m) | $609.80M | $654.78M | $438.51M | (m) | $31.83M | (m) |
| 2024-03-31 | (m) | $574.55M | $548.36M | $336.46M | (m) | $30.06M | (m) |
| 2023-12-31 | (m) | $603.10M | $594.00M | $282.74M | (m) | $30.58M | (m) |
| 2023-09-30 | (m) | $492.12M | $165.16M | $129.65M | (m) | $35.75M | (m) |
| 2023-06-30 | (m) | $476.34M | $208.39M | $129.55M | (m) | $32.02M | (m) |
| 2023-03-31 | (m) | $441.63M | $167.50M | $118.81M | (m) | $26.65M | (m) |
| 2022-12-31 | (m) | $406.24M | $279.83M | $130.87M | (m) | $21.81M | (m) |
| 2022-09-30 | (m) | $420.08M | $104.42M | $184.01M | (m) | $14.81M | (m) |
| 2022-06-30 | (m) | $567.37M | $158.16M | $347.39M | (m) | $15.00M | (m) |
| 2022-03-31 | (m) | $476.78M | $144.18M | $443.62M | (m) | $15.28M | (m) |
| 2021-12-31 | (m) | $509.35M | $189.72M | $583.66M | (m) | $15.86M | (m) |
| 2021-09-30 | (m) | $465.26M | $189.82M | $678.13M | (m) | $15.61M | (m) |
| 2021-06-30 | (m) | $290.96M | $177.35M | $769.73M | (m) | $16.44M | (m) |
| 2021-03-31 | (m) | $250.95M | $146.63M | $841.77M | (m) | $16.23M | (m) |
| 2020-12-31 | (m) | $277.33M | $208.81M | $894.84M | (m) | $18.70M | (m) |
| 2020-09-30 | (m) | $253.82M | $433.97M | $707.05M | (m) | $19.48M | (m) |
| 2020-06-30 | (m) | $201.84M | $158.46M | $340.43M | (m) | $18.37M | (m) |
| 2020-03-31 | (m) | $217.67M | $123.29M | $472.57M | (m) | $19.13M | (m) |
| 2019-12-31 | (m) | $235.86M | $288.03M | $398.54M | (m) | $19.29M | (m) |
| 2019-09-30 | (m) | $183.50M | $523.58M | $185.07M | (m) | $17.11M | (m) |
| 2019-06-30 | (m) | $173.96M | $136.09M | $227.45M | (m) | $16.90M | (m) |
| 2019-03-31 | (m) | $143.05M | $201.14M | $206.02M | (m) | $16.22M | (m) |
| 2018-12-31 | (m) | $166.80M | $169.50M | $58.09M | (m) | $16.12M | (m) |
| 2018-09-30 | (m) | $114.92M | $206.91M | $42.49M | (m) | $13.66M | (m) |
| 2018-06-30 | (m) | $86.47M | $223.79M | $72.32M | (m) | $13.85M | (m) |
| 2018-03-31 | (m) | $72.72M | $97.67M | $80.59M | (m) | $12.36M | (m) |
| 2017-12-31 | (m) | $82.05M | $111.79M | $79.45M | (m) | $10.75M | (m) |
| 2017-09-30 | (m) | $71.90M | $141.84M | $27.47M | (m) | $7.79M | (m) |
| 2017-06-30 | (m) | $67.98M | $133.01M | $48.06M | (m) | $6.91M | (m) |
| 2017-03-31 | (m) | $45.42M | $54.11M | $148.47M | (m) | $1.35M | (m) |
| 2016-12-31 | (m) | $49.62M | $58.32M | $173.34M | (m) | $1.70M | (m) |
| 2016-09-30 | (m) | $48.93M | $50.29M | $198.05M | (m) | $1.30M | (m) |
| 2016-06-30 | (m) | $42.91M | $35.66M | $237.24M | (m) | $1.20M | (m) |
| 2016-03-31 | (m) | $43.89M | $40.16M | $258.55M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $45.39M | $58.02M | $280.90M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $31.70M | $140.71M | $230.81M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $23.08M | $29.22M | $226.00M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $23.91M | $36.83M | $243.64M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $32.48M | $49.75M | $265.49M | (m) | (m) | (m) |
| 2014-09-30 | $210.69M | $17.26M | $52.87M | $156.52M | $1.30M | (m) | 12.21× |
| 2014-06-30 | (m) | $11.58M | $21.17M | $205.69M | (m) | (m) | (m) |
| 2014-03-31 | (m) | $9.24M | $115.86M | $130.73M | (m) | (m) | (m) |
| 2013-12-31 | (m) | $13.13M | $15.41M | $127.05M | (m) | (m) | (m) |
| 2013-09-30 | (m) | $13.92M | $24.04M | $133.18M | (m) | (m) | (m) |
| 2013-06-30 | (m) | $19.79M | $154.10M | $11.58M | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $50.25M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $28.16M | $2.73M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | $14.47M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $22.25M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $28.43M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $28.67M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |